ホームP8A • SGX
add
Cordlife Group Ltd
市場ニュース
財務情報
損益計算書
収益
純利益
| (SGD) | 2024年6月info | 前年比変化率 |
|---|---|---|
収益 | 459.50万 | -67.54% |
営業費用 | 859.05万 | -6.80% |
純利益 | -617.80万 | -655.33% |
純利益率 | -134.45 | -1,810.56% |
1 株当たりの収益 | — | — |
EBITDA | -683.90万 | -615.37% |
実効税率 | 8.73% | — |
貸借対照表
総資産
負債総額
| (SGD) | 2024年6月info | 前年比変化率 |
|---|---|---|
現金および短期投資 | 5954.00万 | -15.89% |
総資産 | 2.24億 | -4.16% |
負債総額 | 1.01億 | 3.31% |
純資産 | 1.23億 | — |
発行済み株式 | 2.56億 | — |
帳簿価格 | 0.32 | — |
総資産利益率 | -8.79% | — |
資本利益率 | -15.66% | — |
キャッシュ フロー
現金の純増減額
| (SGD) | 2024年6月info | 前年比変化率 |
|---|---|---|
純利益 | -617.80万 | -655.33% |
営業キャッシュ フロー | -295.10万 | -192.71% |
投資キャッシュ フロー | 290.45万 | 258.76% |
財務キャッシュ フロー | -54.95万 | -19.59% |
現金の純増減額 | -49.80万 | -153.06% |
フリー キャッシュ フロー | -465.36万 | -1,473.26% |
概要
Incorporated in May 2001, Cordlife Group Limited, is a consumer health company and one of the leading providers of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012.
The Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six key markets namely Singapore, Hong Kong, India, Indonesia and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers a comprehensive suite of diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services.
In January 2018, Cordlife acquired HealthBaby Biotech Co., Limited, the largest private cord blood bank in Hong Kong. Through its majority-owned subsidiary, Stemlife Berhad in Malaysia, Cordlife controls an indirect stake in Thailand's largest private cord blood bank, Thai Stemlife. Cordlife is also the first Singapore private cord blood bank to provide cord blood and cord lining banking services in Myanmar and Vietnam. Wikipedia
CEO
設立
2001/05/02
ウェブサイト
従業員数
111
